TABLE 6.
Liver nodules, clinical data, and laboratory tests at the study.
| Variable | Present (N = 15) | Absent (N = 24) | P-value |
| Age (yrs) | 23.5 (22.4–27.5) | 26.3 (24.6–28.1) | 0.083 |
| Interval from TCPC (yrs) | 21.0 (19.1–22.2) | 21.6 (20.2–22.6) | 0.503 |
| Body weight (kg) | 68.2 ± 13.7 | 69.6 ± 14.9 | 0.758 |
| BMI (kg m–2) | 22.0 (20.1–26.3) | 21.9 (19.8–26.6) | 0.980 |
| Liver elastography (κPa) | 13.7 (12.8–14.7) | 13.4 (12.1–15.7) | 0.688 |
| VO2max (mL/min/kg) | 29.1 ± 4.6 | 28.3 ± 6.4 | 0.661 |
| SPO2 resting (%) | 96 (94–97) | 96 (95–97) | 0.517 |
| SPO2 at VO2max (%) | 86 (85–89) | 88 (85–89) | 0.925 |
| Quality of life (SF-36) | 85 (80–89) | 83 (77–88) | 0.443 |
| GGT (μkat/L) | 1.7 (1.1–2.7) | 1.2 (0.7–1.6) | 0.103 |
| AST (μkat/L) | 0.50 ± 0.10 | 0.48 ± 0.15 | 0.544 |
| ALT (μkat/L) | 0.50 ± 0.16 | 0.53 ± 0.20 | 0.665 |
| Bilirubin (μmol/L) | 14.0 (11.5–21.2) | 17.2 (11.8–21.8) | 0.697 |
| Total protein (g/L) | 74.2 ± 6.1 | 74.7 ± 6.9 | 0.815 |
| Albumin (g/L) | 48.3 ± 4.5 | 47.0 ± 2.9 | 0.297 |
| Prealbumin (g/L) | 0.25 (0.23–0.32) | 0.24 (0.22–0.28) | 0.385 |
| NTproBNP (ng/L) | 90.5 (74.9–166.7) | 103.4 (60.6–183.0) | 0.633 |
| ELF score | 8.8 ± 0.3 | 8.5 ± 0.6 | 0.056 |
| PIIINP (μg/L) | 11.0 ± 3.4 | 8.1 ± 2.9 | 0.009 |
| HA (μg/L) | 20.7 (16.2–27.3) | 18.6 (13.0–28.8) | 0.593 |
| TIMP-1 (μg/L) | 195.8 (182.0–220.7) | 201.5 (177.6–222.2) | 0.762 |
Data are represented as mean ± SD or median (IQR) as appropriate.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ELF, enhanced liver fibrosis test; GGT, gamma glutamyl transferase; HA, hyaluronic acid; NTproBNP, N-terminal pro-brain natriuretic peptide; PIIINP, procollagen III amino-terminal peptide; SPO2, pulse oximetry; TCPC, total cavopulmonary connection; TIMP-1, tissue inhibitors of matrix metaloproteinases; VO2max, maximal oxygen consumption at exercise.